摘要
目的:研究齐多夫定片剂与胶囊在健康人体的生物等效性。方法:20名健康志愿者采用双周期交叉试验,单剂量空腹口服齐多夫定片剂和胶囊剂各300mg,HPLC法测定其血清中齐多夫定浓度,血药浓度-时间数据经DAS2.0统计软件处理,计算主要药代动力学参数,并进行两种制剂的生物等效性评价。结果:齐多夫定片剂与胶囊的主要药代动力学参数分别为:t1/2(0.909±0.308)h和(0.987±0.234)h、Cmax(1.723±0.870)μg/ml和(1.457±0.578)μg/ml、Tmax(0.90±0.69)h和(0.80±0.41)h、AUC0-8h(2.302±0.503)μg·h-1·ml-1和(2.361±0.567)μg·h-1·ml-1。片剂与胶囊比较相对生物利用度为(100.8±25.8)%。结论:齐多夫定片剂与胶囊具有生物等效性。
Objective: To investigate the bioequivalence of zidovudine tablets and capsules in healthy volunteers, Methods: Twenty volunteers were randomly divided into two groups ( test and reference), with double cross-over design. The concentration of zidovudine in serum was determined by HPLC, and pharmacokinetic parameters were calculated with DAS 2.0 practical pharmacokinetics program. Results:The pharmacokinetic parameters of zidovudine tablets and capsules were as follows: t1/2 (0. 909±0. 308 ) h and (0. 987 ± 0.234) h, Cmax ( 1. 723 ± 0.870) μg/ml and ( 1. 457 ± 0. 578 )μg/ml, Tmax ( 0.90 ± 0.69) h and ( 0.80 ± 0.41 ) h, AUC0-8h ( 2. 302 ±0.503)μg·h^-1·ml^-1 and (2. 361 ± 0. 567)μg·h^-1·ml^-1. The relative bioavallbility of zidovudine tablets was (100. 8 ± 25.8) %. Conclusions:The statistical analysis shows that the test and reference preparation are bioequivalent.
出处
《蚌埠医学院学报》
CAS
2008年第2期217-219,共3页
Journal of Bengbu Medical College
关键词
齐多夫定
生物利用度
高效液相色谱法
biological ewailability
zidovudine
high performance liquid ehromatog raphy